Sionna Therapeutics (NASDAQ:SION) Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Sionna Therapeutics (NASDAQ:SION) from a sell rating to a strong sell rating in a report released on Saturday morning.

Several other analysts have also recently issued reports on SION. BTIG Research cut Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 10th. Lifesci Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 10th. Citizens Jmp cut shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 10th. Wedbush downgraded shares of Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research note on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sionna Therapeutics has a consensus rating of “Hold” and a consensus price target of $42.22.

Sionna Therapeutics Stock Down 8.5%

Shares of Sionna Therapeutics stock opened at $5.91 on Friday. Sionna Therapeutics has a twelve month low of $4.01 and a twelve month high of $54.97. The business has a 50-day moving average price of $38.63 and a 200-day moving average price of $38.89. The firm has a market cap of $267.20 million, a price-to-earnings ratio of -2.71 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). On average, equities analysts expect that Sionna Therapeutics will post -2.55 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Peter A. Thompson sold 115,844 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the transaction, the director owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. The trade was a 4.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director directly owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 403,726 shares of company stock valued at $18,259,354. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. State of Wyoming purchased a new stake in Sionna Therapeutics in the 2nd quarter worth about $35,000. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics during the fourth quarter valued at approximately $36,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Sionna Therapeutics during the second quarter valued at approximately $44,000. Russell Investments Group Ltd. bought a new position in shares of Sionna Therapeutics during the third quarter valued at approximately $30,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Sionna Therapeutics in the fourth quarter worth approximately $58,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.